Emergent BioSolutions Inc.
EBS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 64% | -36.6% | 14.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.3% | 43.1% | 53.7% | 70.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | -$0 |
| % Margin | 33.1% | 1.1% | 22.5% | -4.9% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 22.2% | -8.5% | 30.6% | -16.1% |
| EPS | 0.96 | -0.22 | 1.25 | -0.59 |
| % Growth | 536.4% | -117.6% | 311.9% | – |
| EPS Diluted | 0.91 | -0.22 | 1.19 | -0.59 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 41.6% | 16.7% | 33.8% | 10.8% |